Chiesi Nordic
Annelie Barkelund is an accomplished communication professional with extensive experience in public affairs and corporate communications. Currently serving as the Public Affairs and Communications Manager at Chiesi Nordic since May 2020, Annelie previously held the role of Corporate Communications Manager at Nestlé from April 2015 to May 2020, where responsibilities included sustainability and media representation. Prior to Nestlé, Annelie worked as Communications Manager for Northern Europe at Eli Lilly and Company from March 2014 to March 2015, and as Information Manager at Pfizer Pharmaceuticals from August 2007 to February 2014, managing public relations and crisis communications for major brands. Annelie holds a Bachelor's degree in Communication and Media Studies and Political Science from Lund University.
Chiesi Nordic
1 followers
Chiesi is an international, privately-owned pharmaceutical company with its Corporate Head Office based in Parma, Italy. Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the fields of respiratory, neonatology, transplant medicine and rare diseases. Founded in 1935, as a family firm, today, Chiesi spans the globe, employing more than 5000 people in 26 affiliates worldwide and distributes its products in more than 70 countries. In the Nordics, Chiesi Pharma AB employs more than 50 dedicated employees, who are based out of our head office in Central Stockholm, the recently integrated Research and Development Centre at Lidingö outside Stockholm or are part of our experienced field-based sales teams. As with every part of the Chiesi group, we embrace a shared set of values and a common code of ethical conduct. This demands the highest standards of reliability, transparency, and individual accountability in everything we do. It emphasizes the importance of collaborative working, putting people first and exchanging knowledge. Implicit in all of these values is a responsible attitude to the social and environmental impact of our actions. Chiesi is entering important new therapy areas, such as organ transplantation and rare diseases, alongside our treatments for respiratory conditions.